Developed the first genomic test for personalized HER2+ breast cancer treatments
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
Unit News from Breast Cancer
A molecular classification predicts the prognosis and the benefit of a cell cycle inhibitor in metastatic breast cancer
In a study published in the Journal of Clinical Oncology, researchers from the Hospital Clínic-IDIBAPS-UB and SOLTI showed the predictive capacity of1